PDCD1 and neoplasm: Furthermore, when mice were inoculated with a PD1 resistant melanoma cell line, the combination of metformin with anti-PD1 led to tumor regression in 80% of mice, whereas metformin or anti-PD1 monotherapy showed minimal anti-tumor efficacy, suggesting a synergistic effect on T-cell function in the TME (8).